HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT

Karabatić, Sandra; Bećirević, Ilda; Lovrić, Božica; Jovanović, Tihomir

Zdravstveni glasnik, Vol. 12 No. 1, 2026.

Izvorni znanstveni članak

HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT

Sandra Karabatić ; Klinički bolnički centar Zagreb, Kišpatićeva 12, 10 000 Zagreb, Hrvatska & Hrvatsko katoličko sveučilište, Ilica 244, 10 000 Zagreb, Hrvatska & Veleučilište Ivanić-Grad, Moslavačka 11, 10 310 Ivanić-Grad, Hrvatska *
Ilda Bećirević ; Poliklinika Rotim, Miramarska cesta 24, 10 000 Zagreb, Hrvatska
Božica Lovrić ; Opća županijska bolnica Požega, Osječka 107, 34 000 Požega, Hrvatska & Fakultet za dentalnu medicinu i zdravstvo, Sveučilište Josipa Jurja Strossmayera u Osijeku, Crkvena 21, 31 000 Osijek, Hrvatska & Veleučilište Ivanić-Grad, Moslavačka 11, 10 310 Ivanić-Grad, Hrvatska
Tihomir Jovanović ; Fakultet za dentalnu medicinu i zdravstvo, Sveučilište Josipa Jurja Strossmayera u Osijeku, Crkvena 21, 31 000 Osijek, Hrvatska & Opća županijska bolnica Pakrac i bolnica hrvatskih veterana, Bolnička 74, 34 550 Pakrac, Hrvatska & Medicinski fakultet, Sveučilište Josipa Jurja Strossmayera u Osijeku, Josipa Huttlera 4, 31 000 Osijek, Hrvatska

* Dopisni autor.

Puni tekst: engleski pdf 1.403 Kb

str. 8-19

preuzimanja: 0

citiraj

APA 6th Edition

Karabatić, S., Bećirević, I., Lovrić, B. i Jovanović, T. (2026). HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT. Zdravstveni glasnik, 12 (1), 8-19. Preuzeto s https://hrcak.srce.hr/347490

MLA 8th Edition

Karabatić, Sandra, et al. "HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT." Zdravstveni glasnik, vol. 12, br. 1, 2026, str. 8-19. https://hrcak.srce.hr/347490. Citirano 29.05.2026.

Chicago 17th Edition

Karabatić, Sandra, Ilda Bećirević, Božica Lovrić i Tihomir Jovanović. "HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT." Zdravstveni glasnik 12, br. 1 (2026): 8-19. https://hrcak.srce.hr/347490

Harvard

Karabatić, S., et al. (2026). 'HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT', Zdravstveni glasnik, 12(1), str. 8-19. Preuzeto s: https://hrcak.srce.hr/347490 (Datum pristupa: 29.05.2026.)

Vancouver

Karabatić S, Bećirević I, Lovrić B, Jovanović T. HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT. Zdravstveni glasnik [Internet]. 2026 [pristupljeno 29.05.2026.];12(1):8-19. Dostupno na: https://hrcak.srce.hr/347490

IEEE

S. Karabatić, I. Bećirević, B. Lovrić i T. Jovanović, "HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT", Zdravstveni glasnik, vol.12, br. 1, str. 8-19, 2026. [Online]. Dostupno na: https://hrcak.srce.hr/347490. [Citirano: 29.05.2026.]

Sažetak

Background: Lung cancer remains one of the leading causes of cancer-related morbidity and mortality worldwide, while quality of life has become an essential outcome measure in contemporary oncological care.
Aim: To assess the impact of different systemic treatment modalities on the quality of life of patients with lung cancer.
Methods: This prospective study was conducted between January and June 2022 at the Department for Lung and Mediastinal Tumors, Clinic for Pulmonary Diseases Jordanovac, University Hospital Centre Zagreb, Croatia. A total of 162 patients undergoing chemotherapy, immunotherapy, targeted therapy, or combined therapy following surgery were included. Quality of life was assessed using the EORTC QLQ-C30 questionnaire at baseline and two months after treatment initiation. Statistical analyses included the Wilcoxon signed-rank test and Kruskal–Wallis test.
Results: Global health status significantly improved two months after treatment initiation (P = 0.03), while fatigue (P = 0.04) and dyspnea (P = 0.04) decreased compared with baseline values. Financial difficulties increased significantly during treatment (P = 0.009). Patients receiving chemotherapy reported significantly poorer emotional (P = 0.002) and social functioning (P = 0.02) than those receiving immunotherapy. Cognitive functioning was significantly higher in patients treated with immunotherapy compared with chemotherapy or combined therapy (P = 0.001). Overall functioning (P = 0.01) and symptom burden (P = 0.005) were most favorable among patients receiving immunotherapy.
Conclusion: Treatment modality significantly affects quality of life in patients with lung cancer, with immunotherapy demonstrating the most favorable functional and symptomatic outcomes.